WGWladyslaw M.W. Gedroyc

Wladyslaw M.W. Gedroyc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wladyslaw M.W. Gedroyc has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The road to clinical use of high-intensity focused ultrasound for liver cancer: technical and clinical consensus

    by Jean-Francois Aubry, Kim Butts Pauly, Chrit Moonen, Gailter Haar, Mario Ries, Rares Salomir, Sham Sokka, Kevin Michael Sekins, Yerucham Shapira, Fangwei Ye, et al.

    Clinical use of high-intensity focused ultrasound (HIFU) under ultrasound or MR guidance as a non-invasive method for treating tumors is rapidly increasing. Tens of thousands of patients have been treated for uterine fibroid, benign prostate hyperplasia, bone metastases, or prostate cancer. Despite the methods' clinical potential, the liver is a particularly challenging organ for HIFU treatment due to the combined effect of respiratory-induced liver motion, partial blocking by the rib cage, and high perfusion/flow. Several technical and clinical solutions have been developed by various groups during the past 15 years to compensate for these problems. A review of current unmet clinical needs is given here, as well as a consensus from a panel of experts about technical and clinical requirements for upcoming pilot and pivotal studies in order to accelerate the development and adoption of focused ultrasound for the treatment of primary and secondary liver cancer.


  • MR-guided Laser Thermal Ablation of Primary and Secondary Liver Tumours

    by E.A Dick, R Joarder, M de Jode, S.D Taylor-Robinson, H.C Thomas, G.R Foster, W.M.W Gedroyc


  • Feasibility of abdomino-pelvic T1-weighted real-time thermal mapping of laser ablation

    by Elizabeth A. Dick, Paul Wragg, Rita Joarder, Michael de Jode, Gabrielle Lamb, Stuart Gould, Wladyslaw M.W. Gedroyc


  • Magnetic resonance imaging‐guided laser thermal ablation of renal tumours

    by E.A. Dick, R. Joarder, M.G. De Jode, P. Wragg, J.A. Vale, W.M.W. Gedroyc

    Objective To test the hypothesis that magnetic resonance imaging (MRI)‐guided laser thermal ablation (LTA) of inoperable renal tumours is a safe, tolerable and potentially effective treatment . Patients and methods Nine patients (aged 56–81 years) with malignant renal tumours underwent percutaneous LTA under MRI guidance in a 0.5 T open magnet. Real‐time colour thermal mapping was used to monitor tumour ablation, and the follow‐up was with gadolinium‐enhanced MRI at 6 weeks and (where appropriate) 3–4 months after the procedure. Tumour volume and percentage tumour enhancement before and after ablation were compared . The percentage of tumour ablated on real‐time T1‐weighted thermal maps was compared with that on gadolinium‐enhanced follow‐up MRI . Results The mean (range) follow‐up was 16.9 (3–32) months after the first ablation. The mean tumour size did not change significantly, but the mean percentage of viable tumour decreased significantly from 73.7% before to 29.5% after ablation ( P = 0.012, Wilcoxon signed‐ranks test). Thermal maps correlated moderately well with follow‐up MRI in predicting the extent of tumour ablation (Pearson correlation coefficient 0.55). There were two minor and one major complication. Conclusion In this pilot study of patients unsuitable for surgery, MRI‐guided LTA of renal tumours was safe, feasible (being well tolerated by the patient) and significantly reduced enhancing tumour volume by a mean of 45%.


  • Open Access

    Clinical outcomes following percutaneous magnetic resonance image guided laser ablation of symptomatic uterine fibroids

    by J.T. Hindley, P.A. Law, M. Hickey, S.C. Smith, D.L. Lamping, W.M.W. Gedroyc, L. Regan

    BACKGROUND: Fibroids are common benign tumours of the uterus. Percutaneous magnetic resonance (MR) image guided laser ablation provides a minimally invasive, day-case alternative to surgery for the treatment of symptomatic fibroids. METHODS: Women with symptomatic fibroids wishing to avoid surgery were treated with laser ablation. MR thermal mapping ensured that maximal safe energy was applied. Fibroid volume was measured at 3 and 12 months, menstrual blood loss was recorded before and after treatment and a menorrhagia outcomes questionnaire (MOQ) was used to assess satisfaction. RESULTS: A total of 66 patients was treated. There was a significant (P < 0.001) reduction in mean fibroid volume of 31%. This was 41% at 1 year follow-up (P < 0.001). Measured menstrual blood loss in eight patients complaining of excessive bleeding was reduced (P = 0.012). The MOQ total outcome score was not as good as that seen in hysterectomy patients (P = 0.02) but the quality of life/satisfaction score was similar (P = 0.06). CONCLUSION: We have used objective and subjective outcome measures to determine the efficacy of MR guided laser ablation for fibroids. Based on this limited study we are encouraged that this procedure may represent a minimally invasive alternative therapy for fibroids.


  • Open Access

    Ablative therapy for liver tumours

    by E A Dick, S D Taylor-Robinson, H C Thomas, W M W Gedroyc

    Established ablative therapies for the treatment of primary and secondary liver tumours, including percutaneous ethanol injection, cryotherapy, and radiofrequency ablation, are discussed. Newer techniques such as magnetic resonance imaging guided laser interstitial thermal therapy of liver tumours has produced a median survival rate of 40.8 months after treatment. The merits of this newly emerging technique are discussed, together with future developments, such as focused ultrasound therapy, which holds the promise of non-invasive thermoablation treatment on an outpatient basis.